# 4D Molecular Therapeutics, Inc. (FDMT) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/FDMT
## Company Profile
- Ticker: FDMT
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
## Stock Data
- Close: 12.56 USD
- Market cap: 484600874.58 USD
- Last updated: 2026-10-06
## Business Overview
### Genetic Medicines Company
4D Molecular Therapeutics develops genetic medicines using an engineered AAV vector platform known as Therapeutic Vector Evolution. The technology is designed to select vectors for specific tissues and routes of administration rather than relying only on naturally occurring viral capsids.
### 4D-150 Retinal Franchise
4D-150 is an intravitreal dual-transgene therapy that expresses both aflibercept and an anti-VEGF-C molecule. It is being developed for wet age-related macular degeneration and diabetic macular edema with the goal of providing durable control after a single administration.
### Late-Stage Ophthalmology Development
The 4FRONT pivotal program evaluates 4D-150 in wet age-related macular degeneration, while a separate Phase 3 strategy is advancing in diabetic macular edema. These studies position ophthalmology as the company's principal near-term value driver.
### Broader Retinal Pipeline
4D-175 is being developed for geographic atrophy and extends the platform beyond VEGF-driven retinal disease. The program reflects the company's ability to design vectors and payloads for additional degenerative eye conditions.
### Aerosol Gene Therapy for Cystic Fibrosis
4D-710 is an inhaled gene therapy intended to deliver a functional CFTR transgene to airway cells. The program targets people with cystic fibrosis who may not benefit adequately from existing CFTR modulators.
## Why The Stock Is Moving

Following the latest company update, “4DMT to Host Investor Day on October 21, 2026”, FDMT closed down 5.49% at $12.92 on Oct 5, 2026. The move occurred in the trading session associated with this commercial update.

## Future Catalysts

- Initiation of a Phase 3 study of 4D-150 in diabetic macular edema in the third quarter of 2026.
- Two-year SPECTRA data for 4D-150 in diabetic macular edema in the fourth quarter of 2026.
- Updated AEROW clinical data for 4D-710 in cystic fibrosis in the fourth quarter of 2026.
- Topline results from the 4FRONT-1 pivotal study of 4D-150 in the second quarter of 2027.
- Topline results from the 4FRONT-2 pivotal study of 4D-150 in the second half of 2027.

## Recent News
- 2026-10-05 12:00 EST — [4DMT to Host Investor Day on October 21, 2026](https://biopharmsignal.com/news/FDMT/4dmt-to-host-investor-day-on-october-21-2026-a5bee6fa) — Source: 4D Molecular Therapeutics, Inc.
- 2026-09-28 12:00 EST — [4DMT Advances 4D-150 into Phase 3 for Second Large Market Retina Indication with Initiation of 4SIGHT in DME](https://biopharmsignal.com/news/FDMT/4dmt-advances-4d-150-into-phase-3-for-second-large-market-retina-indication-with-faeca691) — Source: 4D Molecular Therapeutics, Inc.
- 2026-09-11 20:05 EST — [4DMT Announces New Employment Inducement Grants](https://biopharmsignal.com/news/FDMT/4dmt-announces-new-employment-inducement-grants-bab3bd91) — Source: 4D Molecular Therapeutics, Inc.
- 2026-08-25 12:00 EST — [4DMT to Participate in Upcoming Investor Conferences](https://biopharmsignal.com/news/FDMT/4dmt-to-participate-in-upcoming-investor-conferences-3c1a936d) — Source: 4D Molecular Therapeutics, Inc.
- 2026-08-13 20:05 EST — [4DMT Reports Second Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones](https://biopharmsignal.com/news/FDMT/4dmt-reports-second-quarter-2026-financial-results-operational-highlights-and-ex-afb95ddd) — Source: 4D Molecular Therapeutics, Inc.